Validation of Computational Approaches for Antiretroviral Dose Optimization

about

Erratum for Siccardi et al., Validation of Computational Approaches for Antiretroviral Dose Optimization.

P921

Q40033560-D9339FCF-EACE-48CC-8843-EB3E9DFBF3D1

P921

Validation of Computational Approaches for Antiretroviral Dose Optimization

Item

http://www.wikidata.org/entity/Q39863986

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Validation of Computational Approaches for Antiretroviral Dose Optimization

@en

Validation of Computational Approaches for Antiretroviral Dose Optimization.

@nl

type

Item

label

Validation of Computational Approaches for Antiretroviral Dose Optimization

@en

Validation of Computational Approaches for Antiretroviral Dose Optimization.

@nl

prefLabel

Validation of Computational Approaches for Antiretroviral Dose Optimization

@en

Validation of Computational Approaches for Antiretroviral Dose Optimization.

@nl

P1476

Validation of Computational Approaches for Antiretroviral Dose Optimization

@en

P2093

Laura Dickinson

http://www.w3.org/2001/XMLSchema#string

P2507

Erratum for Siccardi et al., Validation of Computational Approaches for Antiretroviral Dose Optimization.

P2860

The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda

Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.

Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.

Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement.

Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.

Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.

Physiologically based pharmacokinetic models for anticancer drugs.

Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model.

Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.

P304

3838-3839

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00094-16

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marco Siccardi

Andrew Owen

P577

2016-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27044544

http://www.w3.org/2001/XMLSchema#string

P932

4879416

http://www.w3.org/2001/XMLSchema#string

Validation of Computational Approaches for Antiretroviral Dose Optimization

about

P921

P921

Validation of Computational Approaches for Antiretroviral Dose Optimization

description

name

type

label

prefLabel

P1433

P1476

P2093

P2507

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2507

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932